All News

Fever,temp,man,HA,thermometer

Canakinumab Use in Periodic Febrile Disorders

d Jack Cush, MD

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article
celebration-315079_640.jpg

Effect of Diet on COVID Outcomes

d Jack Cush, MD

A smartphone-based symptom study of COVID-19 patients has shown that a healthy plant-based diet was associated with lower risk and severity of COVID-19, especially amongst those living in areas with higher socioeconomic deprivation.

Read Article
Pills.JIA_.png

Different Regimens but Equal Outcomes in Polyarticular JIA

d Jack Cush, MD

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.

Read Article
infection pneumonia

Pneumocystis Often Lethal in Dermatomyositis

d MedPage Today

Patients with dermatomyositis who were positive for a myositis-specific antibody had a much higher incidence of and mortality associated with Pneumocystis jirovecii infection than patients with other antibody-negative idiopathic inflammatory myopathies, Chinese researchers found.

Read Article
Metanalysis of JAK inhibition (tofacitinib & ruxolitinib) in alopecia areata - 12 studies, 346 Pts, Rx success (using SALT50 resp) was 66%, not influenced by age, sex, subtype. Alopecia recurrence seen w/in 3 mos of JAK D/C (in74%) https://t.co/CBSy4Kci80

Links:

Dr. John Cush RheumNow ( View Tweet)

Popular read— FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors https://t.co/jayl8ufPHn

Links:

Dr. John Cush RheumNow ( View Tweet)

While following individuals and organizations relevant to you is important, so is following hashtags. Read more… https://t.co/pnRFNQA5BW https://t.co/O2Dpm2r0tx

Links:

Dr. John Cush RheumNow ( View Tweet)
Expert Panel Initial Views on FDA Warnings for JAK Inhibitors https://t.co/ujZBwegIJL https://t.co/zCtDhoqiT5

Links:

Dr. John Cush RheumNow ( View Tweet)
CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen. Read more… https://t.co/swXZ4FxB33 #RheumNow #medtwitter https://t.co/zqfd9IPeEf

Links:

Dr. John Cush RheumNow ( View Tweet)
Population study shows risk of H. Zoster in adults to be high among bDMARD and CTX, also increased w/ AZA and HCQ but not MTX SSZ or LEF users. Data from 254065, 1,826311 Pt-Yrs F/U, 6295 new DMARD users, 17024 incident HZ https://t.co/1TeOAWN9LB

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 265 students w/ a positive COVID-19 test looked at 378 close contacts. Infx rates w both persons masked -7.7%, but when unmasked-32.4% (aORs = 4.9;) https://t.co/fYdH33JbWR

Links:

Dr. John Cush RheumNow ( View Tweet)

Cytokine Storm Management available for download. https://t.co/dTAzMVa6SB https://t.co/i6yo351QRN

Links:

Dr. John Cush RheumNow ( View Tweet)
Have an interest in following healthcare trends and updates on Twitter? Dr. Rachel Tate ( @uptoTate ) shared the top three healthcare hashtags to follow. #RheumNow https://t.co/pnRFNQA5BW https://t.co/5a3CzRtzwR

Links:

Dr. John Cush RheumNow ( View Tweet)
Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians. https://t.co/cIWZw6KsuI https://t.co/SWcedXN2jm

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Comments on JAK Inhibitors and FDA Announcement https://t.co/zDYInRQjTl https://t.co/xu9A8I7Frs

Links:

Dr. John Cush RheumNow ( View Tweet)
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i

Links:

Dr. John Cush RheumNow ( View Tweet)

NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD

Links:

Dr. John Cush RheumNow ( View Tweet)

Surveys of 125 clinic patients suggests an improved pt experience by Standardizing appt phone call script, updating appointment package, include a clinic visit prep checklist, to improve pt preparedness and reduce clinic cycle time. https://t.co/5sfBFpag8V

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Causes of DYSGEUSIA (metallic taste): - Antibiotics (clarithromycin, metronidazole tetracycline), Allopurinol, captopril, Lithium, Methazolamide, Metformin, Lunesta and more... heres a video discussion on this. https://t.co/FphprLh1Sf https://t.co/1wkjQxA9UZ https://t.co/kAFaKGiHiG

Links:

Dr. John Cush RheumNow ( View Tweet)
Cytokine Storm Overview Available for Download! https://t.co/XRlx3OJDeR https://t.co/9mGnopNBTs

Links:

Dr. John Cush RheumNow ( View Tweet)
×